Tesaro (Tesaro) Cash, Cash Equivalents, Marketable Securities : $476.8 Mil (As of Sep. 2018)

View and export this data going back to 2012. Start your Free Trial

What is Tesaro Cash, Cash Equivalents, Marketable Securities?

Tesaro's quarterly cash, cash equivalents, marketable securities increased from Mar. 2018 ($498.98 Mil) to Jun. 2018 ($575.10 Mil) but then stayed the same from Jun. 2018 ($575.10 Mil) to Sep. 2018 ($476.81 Mil).

Tesaro's annual cash, cash equivalents, marketable securities increased from Dec. 2015 ($230.15 Mil) to Dec. 2016 ($785.88 Mil) but then declined from Dec. 2016 ($785.88 Mil) to Dec. 2017 ($643.10 Mil).

Tesaro Cash, Cash Equivalents, Marketable Securities Historical Data

The historical data trend for Tesaro's Cash, Cash Equivalents, Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tesaro Cash, Cash Equivalents, Marketable Securities Chart

Tesaro Annual Data

Trend

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Cash, Cash Equivalents, Marketable Securities

Get a 7-Day Free Trial

130.31

256.86

230.15

785.88

643.10

Tesaro Quarterly Data
	Dec13	Mar14	Jun14	Sep14	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18
Cash, Cash Equivalents, Marketable Securities	Get a 7-Day Free Trial															521.27	643.10	498.98	575.10	476.81

Tesaro Cash, Cash Equivalents, Marketable Securities Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Tesaro (NAS:TSRO) Cash, Cash Equivalents, Marketable Securities Explanation

Marketable securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Tesaro Cash, Cash Equivalents, Marketable Securities Related Terms

Thank you for viewing the detailed overview of Tesaro's Cash, Cash Equivalents, Marketable Securities provided by GuruFocus.com. Please click on the following links to see related term pages.

Tesaro (Tesaro) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tesaro Inc (NAS:TSRO) » Definitions » Cash, Cash Equivalents, Marketable Securities

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.tesarobio.com

Tesaro is an oncology-focused biopharmaceutical company with a focus on developing treatments for cancer. Upon successful development and regulatory approval of any of its product candidates, the company intends to pursue commercialization in key product markets, including North America, Europe, and China. Tesaro is currently focused on commercializing products directly in North America, and directly or in partnership with established companies in Europe and China. The company's strategy is to identify, acquire, and develop promising drug candidates, and to commercialize cancer therapeutics that are potentially safer and more effective than existing treatments.

Executives

Mary Lynne Hedley	director, officer: President & COO	C/O TESARO, INC., 1000 WINTER ST., STE 3300, WALTHAM MA 02451
Kavita Patel	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Huber Martin H. Jr.	officer: SVP & Chief Medical Officer	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Moulder Leon O Jr	director, officer: Chief Executive Officer	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
James O Armitage	director	C/O TESARO, INC., 1000 WINTER ST., SUITE 3300, WALTHAM MA 02451
Timothy R Pearson	officer: Exec. VP, CFO	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Garry A Nicholson	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Grant C. Bogle	officer: Sr. VP, Chief Commercial Ofc	C/O TESARO, INC. 1000 WINTER STREET, SUITE 3300 WALTHAM MA 02451
Nea Partners 13, Limited Partnership	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
Nea 13 Gp, Ltd	10 percent owner	1119 ST. PAUL STREET, BALTIMORE MD 21202
New Enterprise Associates 13 Lp	10 percent owner	1119 ST PAUL STREET, BALTIMORE MD 21202
Collier Earl M Jr	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Beth C Seidenberg	director
Joseph L Farmer	officer: Sr VP, Gen Counsel & Secretary	C/O TESARO, INC. 1000 WINTER STREET, SUITE 3300 WALTHAM MA 02451
Patrick J Kerins	10 percent owner